The Complete Guest Journey: What to Expect, and What to Weigh First

How to Read This Page

This page describes a process: what happens, in what order, from first enquiry to twelve-month follow-up. Most of it is logistics — schedules, travel, preparation, aftercare — and that part is straightforward.

But a process page is also where a decision gets made, so the things that should inform that decision come first, before the itinerary: what the evidence supports, what the risks are, what happens if the treatment does not help, and where in the sequence a clinician first exercises judgement.

If you read only one section, read the next four.

Before You Decide

What the evidence actually supports about timing

There is no reliable timeline for how a person responds to cell therapy, and any page that gives you one is making it up. What the research does support is more useful than a milestone chart.

Much of what people feel early is not the treatment. A 2025 systematic review and meta-analysis of randomised trials examined contextual effects in mesenchymal stem cell injection specifically. It found that contextual and placebo response accounts for roughly 63% of the observed treatment response at six months, and about 50% at twelve months¹. That is not a criticism of anyone's experience — the improvement people report is real to them. It means that a substantial majority of early change cannot be attributed to the cells.

Where a measurable effect exists, it is symptomatic. A 2026 meta-analysis of 28 randomised controlled trials found significant improvement in pain and function, and no significant improvement in structural scores on MRI. Its conclusion: these therapies are "primarily symptom-modifying rather than structure-modifying"². Language about "tissue remodelling" or "regeneration continuing over months" is not supported.

Long-term data conflict. One five-year follow-up reported maintained benefit — in 11 patients, uncontrolled³. A double-blind, placebo-controlled trial with 60-month follow-up found scores drifting back toward baseline by year five⁴.

The honest summary: you may feel better, a large part of any early improvement will be contextual, any real effect is likely to be on symptoms rather than structure, and durability beyond a year or two is unresolved.

What the risks are

Mesenchymal stromal cell therapy has a broadly reassuring safety record, and it is not risk-free.

The largest safety synthesis across indications found no association with acute infusional toxicity, organ system complications, infection, death or malignancy — and a significant association with transient fever (OR 16.82, 95% CI 5.33–53.10)⁵. Both halves are the finding.

The intravenous route carries a specific concern. Safety data from one cell source do not transfer to another. Tissue factor expression and the instant blood-mediated inflammatory reaction are particular issues for intravascular delivery⁶, and umbilical cord and adipose-derived preparations carry the highest tissue factor expression, with administration route materially affecting thrombosis risk⁷. Intravenous infusion of umbilical cord-derived cells is the combination those papers identify.

Product quality is not a formality. A 2021 investigation traced infections in 20 patients to a single umbilical cord-derived product marketed as stem cell therapy, with 65% of tested vials contaminated⁸.

The field's own reviewers raise wider concerns. A review of ethical and safety issues in stem cell therapy identifies undesired differentiation and malignant transformation as major safety issues, and — for MSCs specifically — notes concern about the capacity to promote tumour growth and metastasis, alongside overestimated therapeutic potential⁹.

What happens to the cells matters for how you read all of this. Donated cells from an unrelated donor can be given without tissue matching, which is why umbilical cord preparations are used¹³. But they are immune evasive rather than immune privileged — the recipient's immune system does clear them, and the evasion is conditional rather than absolute¹⁴. They do not take up residence and continue working for months. Whatever effect they have is exerted in a relatively short window before clearance, which is one reason claims about tissue rebuilding over six to twelve months do not fit the biology.

What if it doesn't work?

Some people do not improve. No trial reports universal response, and no measurement before treatment reliably predicts who will benefit — response predictors have not been established for this therapy in any indication.

If you do not improve:

• It is not a failure of compliance. Rest, diet and follow-up attendance are sensible, but no evidence links them causally to whether cell therapy works. Any page that tells you otherwise is pre-assigning blame.
• A treatment that has not worked once has not been shown to work on repetition. No trial has tested retreatment after non-response.
• Your other options are unchanged. Intravenous or intra-articular cell therapy does not preclude any conventional treatment.
• You will have spent the money. That is the plain financial reality, and it should be part of the decision before you travel, not after.

Where clinical judgement enters this process

This is stated plainly because it is unusual and because it is easy to miss:

You pay, travel, and receive three intravenous therapies before a physician assesses you.

There is a real argument for this: a physician reviewing six-month-old bloodwork over video can only give a preliminary opinion, whereas on-site examination with same-day labs is a fuller picture. That argument is genuine. It is also compatible with a different sequence — a clinical review before payment and travel — and you are entitled to weigh that yourself.

If you would prefer physician contact before committing, ask for it before you book.

The Process, Phase by Phase

Phase 1: Assessment and candidacy (Week 1)

A seven-step assessment quiz on the Sterling website collects your condition, symptoms and medical history. Your responses activate a condition-specific AI chat that explains what regenerative medicine may offer for your situation, answers questions, invites you to upload existing bloodwork or imaging, and produces a candidacy determination of Strong, Moderate or Weak.

This determination is made by software, not a clinician, and is best treated as a triage step rather than a medical opinion.

A free Strategy Call with a Sterling team member is available. The page is explicit that this is not a physician consultation.

Phase 2: Booking and preparation (Weeks 2–4)

Booking the Discovery programme is a five-step checkout: review, personal details, payment, cohort dates, terms. All guests travel in cohorts of 10–30.

Once booked, your guest portal activates with a trip countdown, preparation checklist, document upload and an AI advisor. Preparation emails follow at T-30, T-14, T-7 and T-1 days.

Medications. Some medicines require adjustment before treatment — blood thinners and anti-inflammatories in particular. Any change must be decided by the physician who prescribed them, working from your full medical picture. Do not discontinue or alter a prescription on the basis of an AI recommendation, a website, or a treatment schedule.

Travel preparation. Arrive the Sunday before a Monday start. Suvarnabhumi Airport (BKK) has direct flights from most major cities. Comprehensive medical travel insurance is mandatory, and should cover emergency treatment abroad, medical evacuation, and trip cancellation. Citizens of most Western nations receive a 30-day visa exemption; check your own nationality's requirements at least four weeks ahead.

General preparation. Staying well hydrated, moderating alcohol, eating well and avoiding injury risk in the week before travel are sensible for any medical trip. They are not treatment steps and no evidence links them to how cell therapy performs.

Phase 3: Arrival and Day 1

A private transfer collects you from arrivals to a 5-star hotel within ten minutes of the partner clinic. A welcome orientation at 5:00 PM covers a facility and laboratory tour, staff introductions, your week's schedule and emergency protocols.

Day 1 schedule:

Bloods are drawn first so that the panel reflects your untreated baseline.

On what these Day 1 therapies do: they are described as preparing the body for cell therapy. No clinical trial has tested exosome or NAD+ pre-treatment as a way of improving cell therapy outcomes, and the general reviews of MSC biology often cited in this context do not study any such protocol¹⁰ ¹¹. They are part of the programme; they are not an evidenced step.

Phase 4: Treatment days (Days 2–5)

Day 2 brings your bloodwork results and your first physician consultation. The physicians examine you, review the labs, check for infection and contraindications, and present a recommendation across the available programmes. You decide whether to proceed at your own pace.

On dose. The programmes differ in cell count. No dose has been established as optimal. In the closest randomised comparison available — a double-blind trial testing 100 million against 200 million cells against placebo — physical performance improved preferentially in the 100-million group, with the six-minute walk test, physical performance battery and lung function improving there and not in the 200-million or placebo groups¹². The higher dose performed worse. Claims that a particular count is optimal, or that splitting a dose across sessions improves the response, are not supported by trial evidence.

The infusion. Administered intravenously over two to three hours in a treatment chair, followed by one to two hours of observation for vital signs and any immediate reaction.

Days 3–4 are recovery days with supportive therapies — hyperbaric oxygen, peptide therapy, nutritional infusions and physiotherapy assessment. These are offered as part of the programme. None has been shown in trials to improve cell therapy outcomes, and they should be understood as comfort and general-wellbeing measures rather than as treatment components.

Day 5 brings a second infusion for guests on programmes that include one.

Phase 5: Recovery and departure (Days 6–7)

Day 6 covers continued vital-sign monitoring, discharge assessment, and — if you feel well and the team agrees — gentle activity or low-impact sightseeing.

Day 7 is departure: a final consultation, recovery guidance stored permanently in your portal, take-home items, onboarding to the twelve-month follow-up programme, and a private transfer to the airport. Arrive at least three hours before an international flight.

Phase 6: The first three months

Rest genuinely matters after any procedure and international travel. A reasonable pattern is minimal activity for the first week or two, gentle walking, then gradual return to normal activity — adjusted to your own condition and to any guidance from your treating physician. Stay well hydrated.

Formal physical therapy, where it is indicated for your condition, has its own evidence base independent of cell therapy and is worth pursuing on that basis.

On tracking your own progress. Keeping a simple record — pain scores, function, sleep, energy — is genuinely useful, both for you and for any clinician you see later. Two things are worth knowing while you do it. First, most people improve somewhat after any treatment, and roughly half to two-thirds of that early change is contextual rather than treatment-specific¹. Second, improvement and deterioration both fluctuate; a single good or bad week is not a trend.

Scheduled questionnaires arrive at 14, 30 and 60 days, tracked in your portal.

Phase 7: Follow-up (Months 3–12)

Assessments at 90 days, 180 days and 12 months cover symptom change, functional status and quality of life against your pre-treatment baseline, with results visualised in your portal.

At twelve months, the team can discuss whether repeat treatment is appropriate. Note that no trial has tested retreatment, either in people who responded or in people who did not, so any such discussion is a clinical judgement rather than an evidence-based recommendation.

Practical Preparation

What to pack

Travel and medical

• Passport valid at least six months, plus photocopies
• Current medications in original pharmacy packaging
• Medical records and imaging — MRI, X-rays, specialist reports, recent bloodwork
• Travel insurance documents with emergency numbers
• Emergency contacts, home and Bangkok

Clothing

• Comfortable loose clothing for treatment days (easy intravenous access)
• Slip-on shoes
• Light layers — Bangkok averages 28–32°C year-round, and indoor spaces are heavily air-conditioned
• Modest attire for temple visits (covered shoulders and knees)
• A robe or cardigan for clinic comfort

Personal

• Phone charger and adapter (Thailand uses 220V, Type A/B/C plugs)
• Books, tablet, headphones — there is significant waiting and resting time
• Eye mask and earplugs
• Refillable water bottle
• A journal, if you intend to track symptoms

Bangkok

The partner clinic is in central Bangkok, with a BTS Skytrain station within a five-minute walk and Bumrungrad International Hospital ten minutes away. Where recovery permits and the medical team agrees, low-impact activities are available — temple visits, river cruises, floating markets. Thai massage requires medical clearance.

Dining accommodates most dietary requirements. The concierge team can advise on restaurants and spice levels.

Language and support

The medical and administrative team speaks fluent English, translator services are available for several other languages, and all medical documents are provided in English. Support during your stay includes a Sterling coordinator, on-site medical staff during operating hours, a 24/7 emergency line, and the guest cohort you travel with. Companions are welcome and companion programmes are available.

What the Programme Includes

The following are the commercial and operational terms of the offering. They are business facts, not research findings, and are stated here without citation.

• Discovery programme: $5,999, including a $5,000 credit toward any treatment programme selected on-site
• Cohort travel in groups of 10–30 guests
• Private airport transfers; 5-star hotel accommodation within ten minutes of the clinic
• Comprehensive blood panel and physician consultation on site
• Access to the Sterling guest portal and AI advisor before, during and after treatment
• Twelve months of structured follow-up with scheduled questionnaires
• Cell preparation in an ISO 5 cleanroom facility with documented quality control and traceability
• Mandatory medical travel insurance including evacuation cover (arranged by the guest)

Treatment programmes, cell counts and their prices are presented on site after physician consultation.

Frequently Asked Questions

Will I definitely improve?

No. Some people do not improve, and no assessment before treatment reliably predicts who will. Where benefit occurs it is more likely to be symptomatic than structural², and roughly half to two-thirds of early change is contextual rather than treatment-specific¹.

How quickly should I expect to feel something?

There is no established timeline, and this page no longer offers one. Trials measure outcomes at fixed points — commonly six and twelve months — rather than tracking a recovery curve, so any week-by-week schedule is invented.

Why do I not speak to a physician before I travel?

The stated rationale is that on-site examination with same-day bloodwork gives a fuller picture than a video call reviewing older records. That argument is genuine. It also means candidacy is initially determined by an AI tool, and payment and Day 1 infusions precede clinical assessment. If you would prefer physician contact before committing, ask before booking.

How many cells will I receive, and is more better?

Programmes differ in cell count, and the recommendation is made on site. More is not reliably better — in the closest randomised comparison, the lower of two doses performed better on every physical outcome¹².

What are the risks?

Transient fever is the one adverse event significantly associated with MSC therapy in pooled data (OR 16.82, 95% CI 5.33–53.10), alongside no association with organ toxicity, infection, malignancy or death⁵. Intravenous delivery of umbilical cord-derived cells carries a specific tissue-factor–related thrombotic consideration⁶ ⁷, and unregulated products have caused infections⁸.

Do the Day 1 therapies improve the outcome?

No trial has tested exosome or NAD+ pre-treatment for that purpose. They are part of the programme, not an evidenced step.

If it doesn't work, can I have it again?

No trial has tested retreatment, in responders or non-responders. Any such recommendation is a clinical judgement rather than an evidence-based one.

Is my improvement "real" if it's a contextual effect?

The improvement you feel is real. What the contextual-effect research tells you is that a large share of it would likely have occurred with a convincing sham procedure¹ — which matters for deciding whether to repeat, recommend or pay for the treatment again, not for whether your experience is genuine.

Can my partner come?

Yes. Companion programmes include transfers, double-occupancy accommodation and concierge support.

Do I need to speak Thai?

No. The medical and administrative team speaks fluent English, with translator services available for other languages.